Genmab A/S (NASDAQ:GMAB – Get Rating) has been assigned a consensus rating of “Hold” from the twelve analysts that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation and two have given a buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $547.62.
GMAB has been the subject of a number of research analyst reports. Morgan Stanley upped their price target on Genmab A/S from $29.00 to $31.00 and gave the stock an “underweight” rating in a report on Monday, August 15th. TheStreet upgraded shares of Genmab A/S from a “c+” rating to a “b” rating in a report on Wednesday, August 31st. SVB Leerink increased their target price on shares of Genmab A/S from $30.00 to $31.00 and gave the company a “market perform” rating in a research note on Thursday, August 11th. HC Wainwright boosted their price target on Genmab A/S from $49.00 to $51.00 and gave the company a “buy” rating in a research note on Monday, August 22nd. Finally, BMO Capital Markets initiated coverage on Genmab A/S in a research report on Thursday, June 23rd. They issued a “market perform” rating and a $34.73 price objective for the company.
Genmab A/S Price Performance
Shares of GMAB opened at $31.83 on Friday. The business’s 50-day moving average is $35.68 and its 200-day moving average is $33.96. The company has a market capitalization of $20.95 billion, a price-to-earnings ratio of 35.37, a P/E/G ratio of 1.27 and a beta of 0.85. Genmab A/S has a fifty-two week low of $26.19 and a fifty-two week high of $47.28.
Genmab A/S (NASDAQ:GMAB – Get Rating) last announced its earnings results on Wednesday, August 10th. The company reported $0.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.21 by $0.20. The firm had revenue of $452.86 million during the quarter, compared to analysts’ expectations of $435.40 million. Genmab A/S had a return on equity of 17.12% and a net margin of 38.42%. Equities research analysts expect that Genmab A/S will post 1.02 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of GMAB. Covestor Ltd acquired a new stake in shares of Genmab A/S during the 4th quarter worth about $37,000. International Biotechnology Trust PLC acquired a new position in shares of Genmab A/S in the 2nd quarter worth approximately $57,000. Captrust Financial Advisors grew its position in Genmab A/S by 62.0% during the 1st quarter. Captrust Financial Advisors now owns 2,658 shares of the company’s stock worth $96,000 after acquiring an additional 1,017 shares during the last quarter. Private Capital Group LLC increased its holdings in Genmab A/S by 14.1% during the 2nd quarter. Private Capital Group LLC now owns 2,677 shares of the company’s stock valued at $87,000 after purchasing an additional 331 shares in the last quarter. Finally, Seaport Global Advisors LLC bought a new position in Genmab A/S in the 4th quarter valued at $1,142,000. 5.51% of the stock is currently owned by institutional investors and hedge funds.
Genmab A/S Company Profile
(Get Rating)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.